Challenges in Prescribing PCSK9 Inhibitors Survey

The National Lipid Association (NLA) is committed to enhancing the practice of lipid management in clinical medicine. A major component is having access to all therapies to properly treat patients with the management of lipid disorders.

PCSK9 inhibitors are one therapy that patients have trouble receiving access to even when properly prescribed. To help improve patient access to PCSK9 inhibitors, the NLA is conducting an important survey for healthcare providers to share their experiences with the PCSK9 inhibitor prescription approval process. The NLA will share the results at national scientific meetings and in publications. The survey can be completed by both prescribers and non-prescribers who work with patients in attempting to gain access to PCSK9 therapy.

We are asking the entire membership of the NLA to take this survey that focuses on the challenges of getting patients access to PCSK9 therapy. We need to have as much input as possible, and strongly encourage your participation.

We sincerely hope you will agree to spend 15-20 minutes to complete this online survey. The survey is only open until October 14, 2016, and must be completed by that date. We thank you in advance for your participation.

 Click Here to Complete Survey 

If you have any questions regarding the study or its implementation, please contact Rob Talbert, NLA Projects and Group Manager, at 904-309-6228.